|Bid||102.50 x 100|
|Ask||105.32 x 100|
|Day's Range||103.44 - 104.85|
|52 Week Range||59.27 - 104.85|
|PE Ratio (TTM)||25.21|
|Forward Dividend & Yield||2.84 (2.77%)|
|1y Target Est||N/A|
We present four large cap drug companies, which are expected to repeat their last year's industry beating performance in 2018.
Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.
Short interest is extremely low for ABBV with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABBV. The net inflows of $13.20 billion over the last one-month into ETFs that hold ABBV are among the highest of the last year, but the rate of growth is slowing.
Some of the biggest U.S. companies are promising significant annual savings, bigger pension contributions, higher dividend payments and more extensive stock buybacks as executives start to discuss the ...
Novartis (NVS) Biologics License Application (BLA) for the proposed biosimilar of blockbuster drug Humira was accepted by the FDA under the 351 (k) pathway.
Short interest is extremely low for ABBV with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABBV. Over the last month, growth of ETFs holding ABBV is favorable, with net inflows of $18.30 billion.
Should You Jump on the Marijuana Bandwagon? Investors interested in accessing the marijuana industry have several options. In the US, Scotts Miracle-Gro (SMG) has invested in companies that are positioned to serve the cannabis market.
Should You Jump on the Marijuana Bandwagon? Investing in the marijuana industry—at least in its current stage in the US—certainly comes with its own set of risks. In the preceding part of this series, we discussed how the marijuana plant contains CBD (cannabidiol), which is used for medicinal (XLV) purposes.
In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.
Retirement investing is a bit different from regular investing, and not because it depends more on dividend investing. Dividend Aristocrats were an important part of the retired investor’s portfolio then, because their cash flow is not only so fantastic that they can continue raising dividends year after year, but because they also have enough growth in some cases to boost annual returns to that important 10% level.
Investors are fleeing from testosterone drugmaker Lipocine, but its FDA woes portend bigger challenges for companies developing new versions of the embattled hormone.
In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall and a 26.8% reported fall year-over-year (or YoY). The company reported HCV sales of close to $60 million from the US market in 3Q17, a YoY fall of ~19.5%. AbbVie also reported HCV sales of close to $216 million from international markets in 3Q17, a YoY fall of 29.8% on an operational basis and a fall of 28.7% on a reported basis.
On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application (or NDA) for its investigational drug Elagolix, which is used for managing endometriosis-related pain, had been granted priority review by the FDA. AbbVie has developed Elagolix in collaboration with Neurocrine Biosciences (NBIX). AbbVie expects this oral gonadotropin-releasing hormone (or GnRH) antagonist to be approved by its Prescription Drug User Fee Act (or PDUFA) date in 2Q18.
Australia earlier this month joined the growing list of nations that have legalized medical marijuana. The Marijuana Index is a series of equally weighted stock indexes that track the leading cannabis stocks in the U.S. and Canada. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with a market cap of $3.34 billion, produces a multiple sclerosis treatment using nabiximols, an herbal preparation containing a defined quantity of specific cannabinoids with potential analgesic activity.
When Miles White was named CEO of Abbott Laboratories, he was the youngest head of a major health care company. Now he's one of the longest serving.